Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding

• ClinicalTrials.gov Identifier: NCT01307007
• Recruitment Status: Completed
• First Posted: March 2, 2011
• Results First Posted: June 27, 2017
• Last Update Posted: February 19, 2018
• Sponsor: American Regent, Inc.
• Information provided by (Responsible Party): American Regent, Inc.

Study Description

Brief Summary:

The primary objective of this study is to assess the safety of an investigational intravenous iron (ferric carboxymaltose [FCM]) or an equal dose of iron dextran and explore the mechanism of hypophosphatemia following administration of FCM or that of an equal dose of iron dextran when treating women with iron deficiency anemia due to heavy uterine bleeding (HUB).

Condition or disease	Intervention/treatment	Phase
Iron Deficiency Anemia	Drug: Ferric Carboxymaltose (FCM); Drug: Iron Dextran Injection	Phase 2

Detailed Description:

To assess the safety of an investigational intravenous iron (ferric carboxymaltose [FCM]) or an equal dose of iron dextran and explore the mechanism of hypophosphatemia following administration of FCM or that of an equal dose of iron dextran when treating women with iron deficiency anemia due to heavy uterine bleeding (HUB).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 69 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Controlled Study to Investigate the Safety and Explore the Mechanism of Hypophosphatemia With Intravenous Ferric Carboxymaltose (FCM) Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding
• Study Start Date: September 2010
• Actual Primary Completion Date: May 2011
• Actual Study Completion Date: August 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ferric Carboxymaltose (FCM); 15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0	Drug: Ferric Carboxymaltose (FCM); 15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0; Other Name: Injectafer
Active Comparator: Iron Dextran Injection; Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.	Drug: Iron Dextran Injection; Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.; Other Name: Dexferrum and INFeD

Outcome Measures

Primary Outcome Measures :

1. Changes in Blood Markers [ Time Frame: Day 35 ]
   Changes in blood markers of phosphate

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Female subjects > or = to 18 years of age
• History of Heavy Uterine Bleeding within the past 6 months
• Screening visit central laboratory Hgb < 12 g/dL
• Screening Visit ferritin < or = to 100 ng/mL or < or = to 300 when transferrin saturation (TSAT) is < or = to 30%
• Demonstrate the ability to understand the requirements of the study, willingness to abide by study restrictions and to return for the required assessments

Exclusion Criteria:

• Known hypersensitivity reaction to any component of ferric carboxymaltose or iron dextran
• Previously randomized in a clinical study of ferric carboxymaltose
• Requires dialysis for treatment of chronic kidney disease
• Chronic kidney disease, marked by estimated glomerular filtration rate < 60 ml/min/1.73m squared
• Previous kidney transplant
• History of primary hypophosphatemic disorder
• Hypophosphatemia < 2.6 mg/dl
• No evidence of iron deficiency
• During the 10 day period prior to screening has been treated with intravenous iron
• During the 30 day period prior to screening or during the study period has or will be treated with erythropoiesis stimulating agents (ESA) in a regimen that is off label
• During the 30 day period prior to screening or during the study period has or will be treated with a red blood cell transfusion, radiotherapy and/or chemotherapy
• During the 30 day period prior to screening or during the study period has or will require a surgical procedure that necessitates general anesthesia
• Any non-viral infection
• Aspartate aminotransferase (AST) or Alanine Aminotransferase (ALT) at screening, as determined by central labs, greater than 1.5 times the upper limit of normal
• Known positive hepatitis with evidence of active disease
• Received an investigational drug within 30 days of screening
• Alcohol or drug abuse within the past 6 months
• Hemochromatosis or other iron storage disorders
• Malignancy history within the past 5 years other than basal or squamous cell skin cancer
• Any other laboratory abnormality, medical condition or psychiatric disorders which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements
• Pregnant or sexually-active female subjects who are of childbearing potential and who are not willing to use an acceptable form of contraception
• Untreated primary hyperparathyroidism
• Untreated gastrointestinal malabsorption (e.g., sprue)

Contacts and Locations

Sponsors and Collaborators

American Regent, Inc.

Investigators

• Study Director: Mark Falone, MD; American Regent, Inc.

More Information

Additional Information:

FGF23; IRON; PHOSPHATE; PTH; VITAMIN D 

Publications of Results:

Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013 Aug;28(8):1793-803. doi: 10.1002/jbmr.1923.

• Responsible Party: American Regent, Inc.
• ClinicalTrials.gov Identifier: NCT01307007
• Other Study ID Numbers: 1VIT08023
• First Posted: March 2, 2011
• Results First Posted: June 27, 2017
• Last Update Posted: February 19, 2018
• Last Verified: January 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Uterine Hemorrhage; Anemia, Iron-Deficiency; Hypophosphatemia; Hemorrhage; Pathologic Processes; Anemia, Hypochromic; Anemia; Hematologic Diseases; Iron Metabolism Disorders; Metabolic Diseases; Uterine Diseases; Genital Diseases, Female; Phosphorus Metabolism Disorders; Dextrans; Iron-Dextran Complex; Anticoagulants; Plasma Substitutes; Blood Substitutes; Hematinics